(Reuters Health) - A component of green tea combined with a low dose of a COX-2 inhibitor may act in concert to slow the spread of human prostate cancer.
In the journal Clinical Cancer Research, they report that low doses of the COX-2 inhibitor celecoxib (sold as Celebrex), given along with a green tea polyphenol slowed the growth of prostate cancer in cell cultures and in a mouse model of the disease.
"Celecoxib and green tea have a synergistic effect, each triggering cellular pathways, that, combined, are more powerful than either agent alone," Dr. Hasan Mukhtar from the University of Wisconsin, Madison, said in a statement.(Read entire article)
A component of green tea, combined with low doses of the cox-2 inhibitor painkiller Celebrex, may be able to slow prostate cancer growth, according to a U.S. study.
Previous research found that, individually, both the green tea polyphenol epigallocatechin-3-gallate (EGCG), a known antioxidant, and cox-2 inhibitors helped fight prostate cancer in animals.
In this study of cultured human prostate cancer cells and mice, researchers at the University of Wisconsin-Madison found that a combination of EGCG and the cox-2 inhibitor celecoxib (Celebrex) was 15 percent to 28 percent more effective in slowing the growth of cancer cells than either agent alone. (Read entire article)